BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research
BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today announced a strategic supply agreement with NorthStar Medical Radioisotopes (NorthStar) to secure a reliable supply and provide Actinium-225 (Ac-225) for use in preclinical studies conducted by BIOEMTECH customers.
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced a collaboration to develop and produce novel radiopharmaceuticals for the treatment of cancer.
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Adam Lynch as Vice President, Corporate Development and External Affairs
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than 20 years of experience in the healthcare industry, most recently as interim Chief Financial Officer for a 200-bed acute care hospital. Mr. Lynch will report to NorthStar President and Chief Executive Officer Stephen Merrick.
